The history of MF59®adjuvant: a phoenix that arose from the ashes

Effectiveness of Adjuvanted Influenza Vaccination in Elderly Subjects in Northern Italy

(2012) S. Mannino et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

Safety of MF59-adjuvanted A/H1N1 influenza vaccine in pregnancy: a comparative cohort study

(2012) Terho Heikkinen et al.   AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY

Safety and immunogenicity of a monovalent MF59®-adjuvanted A/H1N1 vaccine in HIV-infected children and young adults

(2012) Paolo Palma et al.   BIOLOGICALS

Comparison of the Long-Term Immunogenicity of Two Pandemic Influenza A/H1N1 2009 Vaccines, the MF59-Adjuvanted and Unadjuvanted Vaccines, in Adults

(2012) Joon Young Song et al.   Clinical and Vaccine Immunology

Risk of Adverse Fetal Outcomes Following Administration of a Pandemic Influenza A(H1N1) Vaccine During Pregnancy

(2012) Björn Pasternak et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans

(2012) Tom M Wilkinson et al.   NATURE MEDICINE

Dose-range Study of MF59-adjuvanted Versus Nonadjuvanted Monovalent A/H1N1 Pandemic Influenza Vaccine in Six- to Less Than Thirty-Six-month-old Children

(2012) Stan L. Block et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Identification of Antigen and Adjuvant Doses Resulting in Optimal Immunogenicity and Antibody Persistence up to 1 Year After Immunization With a Pandemic A/H1N1 Influenza Vaccine in Children 3 to ,9 Years of Age

(2012) Cynthia Nassim et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Increased Incidence and Clinical Picture of Childhood Narcolepsy following the 2009 H1N1 Pandemic Vaccination Campaign in Finland

(2012) Markku Partinen et al.   PLoS One

AS03 Adjuvanted AH1N1 Vaccine Associated with an Abrupt Increase in the Incidence of Childhood Narcolepsy in Finland

(2012) Hanna Nohynek et al.   PLoS One

Immunogenicity and safety of a two-dose regimen of a combined measles, mumps, rubella and varicella live vaccine (ProQuad®) in infants from 9 months of age

(2012) Timo Vesikari et al.   VACCINE

A randomized clinical trial to identify the optimal antigen and MF59® adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects

(2012) Christoph Hatz et al.   VACCINE

A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations

(2012) Christoph Hatz et al.   VACCINE

One dose of an MF59-adjuvanted pandemic A/H1N1 vaccine recruits pre-existing immune memory and induces the rapid rise of neutralizing antibodies

(2012) Elisa Faenzi et al.   VACCINE

The mechanism of action of MF59 – An innately attractive adjuvant formulation

(2012) D.T. O’Hagan et al.   VACCINE

Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59®adjuvant

(2012) Giovanni Della Cioppa et al.   Human Vaccines & Immunotherapeutics

2009 pandemic influenza A (H1N1) in pregnancy: a systematic review of the literature

(2011) Laura G. Mosby et al.   AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY

Long-Term Immunogenicity after One and Two Doses of a Monovalent MF59-Adjuvanted A/H1N1 Influenza Virus Vaccine Coadministered with the Seasonal 2009-2010 Nonadjuvanted Influenza Virus Vaccine in HIV-Infected Children, Adolescents, and Young Adults in a Randomized Controlled Trial

(2011) Alessandra Viganò et al.   Clinical and Vaccine Immunology

Immunogenicity and Safety of the Influenza A/H1N1 2009 Inactivated Split-Virus Vaccine in Young and Older Adults: MF59-Adjuvanted Vaccine versus Nonadjuvanted Vaccine

(2011) Hee Jin Cheong et al.   Clinical and Vaccine Immunology

Long-lasting immunogenicity and safety of a 2009 pandemic influenza A(H1N1) MF59-adjuvanted vaccine when co-administered with a 2009-2010 seasonal influenza vaccine in young patients with Type 1 diabetes mellitus

(2011) G. V. Zuccotti et al.   DIABETIC MEDICINE

MF59 adjuvant: the best insurance against influenza strain diversity

(2011) Derek T O’Hagan et al.   Expert Review of Vaccines

H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy

(2011) J.-F. Rahier et al.   GUT

Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations

(2011) Angelika Banzhoff et al.   Human vaccines & immunotherapeutics

Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection

(2011) Jens Wrammert et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Aluminum Adjuvant Dose Guidelines in Vaccine Formulation for Preclinical Evaluations

(2011) Simone Vecchi et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Hemagglutination Inhibition Antibody Titers as a Correlate of Protection for Inactivated Influenza Vaccines in Children

(2011) Steven Black et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Response to 2009 Pandemic Influenza A (H1N1) Vaccine in HIV-Infected Patients and the Influence of Prior Seasonal Influenza Vaccination

(2011) Darius Soonawala et al.   PLoS One

Adverse Events Following Pandemic A (H1N1) 2009 Monovalent Vaccines in Pregnant Women — Taiwan, November 2009–August 2010

(2011) Wan-Ting Huang et al.   PLoS One

Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88

(2011) A. Seubert et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

MF59 Adjuvant Enhances Diversity and Affinity of Antibody-Mediated Immune Response to Pandemic Influenza Vaccines

(2011) S. Khurana et al.   Science Translational Medicine

National Estimates of Seroincidence and Seroprevalence for Herpes Simplex Virus Type 1 and Type 2 Among US Military Adults Aged 18 to 29 Years

(2011) William F. Page et al.   SEXUALLY TRANSMITTED DISEASES

Immunogenicity and safety profile of the monovalent A/H1N1 MF59-adjuvanted vaccine in patients affected by cystic fibrosis

(2011) F. Alghisi et al.   THORAX

An alternative renewable source of squalene for use in emulsion adjuvants

(2011) Luis A. Brito et al.   VACCINE

Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients

(2011) Massimiliano Fabbiani et al.   VACCINE

Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy

(2011) Elena Pariani et al.   VACCINE

Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes

(2011) Samuele Calabro et al.   VACCINE

Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity

(2011) Sandra Morel et al.   VACCINE

Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents

(2011) Susanna Esposito et al.   VACCINE

Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children

(2011) Sara Meier et al.   VACCINE

Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases

(2011) Ori Elkayam et al.   ARTHRITIS CARE & RESEARCH

Comparison of half and full doses of an MF59-adjuvanted cell culture-derived A/H1N1v vaccine in Japanese children

(2010) Yuji Yasuda et al.   ADVANCES IN THERAPY

Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals

(2010) Anna Kajaste-Rudnitski et al.   AIDS

Monitoring Adverse Events of the Vaccination Campaign Against Influenza A (H1N1) in the Netherlands

(2010) Eugène P. van Puijenbroek et al.   DRUG SAFETY

Transplacental Antibody Transfer Following Maternal Immunization With a Pandemic 2009 Influenza A(H1N1) MF59-Adjuvanted Vaccine

(2010) GianVincenzo Zuccotti et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Vaccinate before the next pandemic?

(2010) Klaus Stöhr   NATURE

Vaccines with MF59 Adjuvant Expand the Antibody Repertoire to Target Protective Sites of Pandemic Avian H5N1 Influenza Virus

(2010) S. Khurana et al.   Science Translational Medicine

Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates

(2010) Filippo Ansaldi et al.   VACCINE

The path to a successful vaccine adjuvant – ‘The long and winding road’

(2009) Derek T. O’Hagan et al.   DRUG DISCOVERY TODAY

Response to a Monovalent 2009 Influenza A (H1N1) Vaccine

(2009) Michael E. Greenberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vaccine Prevention of Maternal Cytomegalovirus Infection

(2009) Robert F. Pass et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trial of 2009 Influenza A (H1N1) Monovalent MF59-Adjuvanted Vaccine

(2009) Tristan W. Clark et al.   NEW ENGLAND JOURNAL OF MEDICINE

Responses to 2009 H1N1 Vaccine in Children 3 to 17 Years of Age

(2009) Adriano Arguedas et al.   NEW ENGLAND JOURNAL OF MEDICINE

Enhanced Immunogenicity of Seasonal Influenza Vaccines in Young Children Using MF59 Adjuvant

(2009) Timo Vesikari et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

MF59 Emulsion Is an Effective Delivery System for a Synthetic TLR4 Agonist (E6020)

(2009) Barbara C. Baudner et al.   PHARMACEUTICAL RESEARCH

Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine

(2009) G. Galli et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels

(2009) G. Galli et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

MF59®-adjuvanted influenza vaccine (FLUAD®) in children: Safety and immunogenicity following a second year seasonal vaccination

(2009) T. Vesikari et al.   VACCINE

Cross-reactive antibodies in middle-aged and elderly volunteers after MF59-adjuvanted subunit trivalent influenza vaccine against B viruses of the B/Victoria or B/Yamagata lineages

(2009) B. Camilloni et al.   VACCINE

Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: Safety and immunogenicity of a phase 1/2 clinical trial

(2009) Wendy Keitel et al.   VACCINE

Exposure to MF59-adjuvanted influenza vaccines during pregnancy—A retrospective analysis

(2009) Theodore Tsai et al.   VACCINE

Effectiveness of Maternal Influenza Immunization in Mothers and Infants

(2008) K. Zaman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Influence of Prior Influenza Vaccination on Antibody and B-Cell Responses

(2008) Sanae Sasaki et al.   PLoS One

Molecular and cellular signatures of human vaccine adjuvants

(2008) F. Mosca et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Safety of MF59™ adjuvant

(2008) Viola Schultze et al.   VACCINE

Cross-protection by MF59™-adjuvanted influenza vaccine: Neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses

(2008) Filippo Ansaldi et al.   VACCINE